SAMe is the body's universal methyl donor — involved in 200+ methylation reactions including neurotransmitter synthesis, DNA methylation, and cartilage repair. It has STRONG evidence for three distinct indications: (1) depression (meta-analysis: equivalent to tricyclic antidepressants), (2) osteoarthritis (comparable to NSAIDs with NO GI side effects), and (3) liver disease (improves cholestasis and hepatocyte function). Our research shows SAMe is one of the very few supplements effective for depression that has been studied in large, well-designed trials. The limitation: it's expensive ($30-60/month at therapeutic doses) and unstable (degrades with heat, moisture, and time).
SAMe donates methyl groups (-CH₃) to over 200 biochemical reactions: (1) Neurotransmitter synthesis — methylation is required for serotonin, dopamine, and norepinephrine production (catechol-O-methyltransferase, COMT, requires SAMe); (2) Cartilage repair — SAMe provides sulfur for glycosaminoglycan (GAG) synthesis in chondrocytes AND reduces inflammatory cytokines (IL-1β, TNF-α) in joints; (3) Liver function — SAMe is required for hepatic phospholipid synthesis (phosphatidylcholine) and glutathione production; liver disease depletes SAMe, creating a vicious cycle; (4) DNA/epigenetic — SAMe methylates DNA (CpG islands), regulating gene expression. After donating its methyl group, SAMe becomes homocysteine (which is recycled back to methionine via B12/folate pathway).
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.